Trial Profile
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Compare the Efficacy and Safety of Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary) ; Ambrisentan; Tadalafil
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors United Therapeutics Corporation
- 31 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 19 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 Oct 2017.
- 24 Dec 2016 New trial record